References
- Stocking KL, Jones JC, Everds NE, et al. Use of Low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells. Comp Med 2009;59:37-45
- Lip GYH, Chin BSP, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002;3:27-34
- Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines. 8th edn. Chest 2008;133:141S-59
- Griffiths GO, Burns S, Noble SI, et al. FRAGMATIC: a randomized phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer 2009;9:1-9
- Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17
- Ofosu FA. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. Thromb Haemost 2012;107:201-14
- Padilla A, Gray E, Pepper DS, et al. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992;82:406-13
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5
- Wallentin L. Fragmin during instability in coronary artery disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8
- Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-8
- Cohen M, Demers C, Gurfinkel EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non–Q-wave coronary events. Am J Cardiol 1998;82:19L-24
- DeBernardo RL, Perkins RB, Littell RD, et al. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. DVT prophylaxis in gynecologic oncology surgery. Obstet Gynecol 2005;105:1006-11
- Jawed F, Walter J, Debra H, et al. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998;82:3L-10
- Samama M. Contemporary laboratory monitoring of low molecular weight heparins. Thromb Haemost 1995;15:119-23
- Abbate R, Gori AM, Farsi A, et al. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998;82:33L-6
- Fragmin [prescribing information]. NY: Pfizer Inc.; Germany: Vetter Pharma-Fertigung, 2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020287s050lbl.pdf. Accessed June 1, 2012
- Center for Drug Evaluation and Research. U.S. Food and Drug Administration. Guidance for Industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. 2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf. Accessed June 1, 2012
- Feng L, Shen-Tu J, Liu J, et al. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects. Clin Ther 2009;31:1559-67
- Bara L, Mardiguian J, Samama M. In vitro effect on heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990;57:585-92
- Stief TW. Innovative tests of plasmatic hemostasis. Lab Med 2008;39:225-30